A genetically-engineered virus has prolonged the lives of terminally ill liver cancer patients in a small clinical trial. The results will need confirming in larger studies, but Cancer Research UK welcomed the advance as "an exciting step forward". Read more here.
Study mentioned: Heo J, et al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med. 2013 Feb 10. [Epub ahead of print] PMID: 23396206
No comments:
Post a Comment